... individual
risks forbreastcancer 60-85% and may be identified in 5-10% of all breastcancer cases.
28
Personal history of noninvasive breastcancer or previous abnormal breast biopsy containing ... participants for women age 40-49 years that
reported relative risk (RR) reduction in breastcancer mortality. We conducted similar updates
for other age groups for context. We used breastcancer ... risk forbreastcancer mortality of 0.83 (95% confidence
interval [CI], 0.66-1.04) for women randomly assigned to screening, and a number needed to
invite for screening to prevent one breast cancer...
... background for our information in this
leaflet below.
SCREENING FORBREASTCANCER
WITH MAMMOGRAPHY
What are the benefits and harms of attending a
screening programme forbreast cancer? ... treatment forbreastcancer in Norway: comparative
analysis of cancer registry data. BMJ 2011;343:d4692.
20. NHS cancer screening programmes. BASO Breast Audit 1999/2000.
www.cancerscreening.nhs.uk/breastscreen/publications.html ... disease and cancer.
It therefore no longer seems reasonable to attend forbreast
cancer screening. In fact, by avoiding going to screening, a woman
will lower her risk of getting a breast cancer...
... subtypes in
clinical breast cancer. Int J Cancer 2000, 89:209-212.
19. Elston W, Ellis IO: Pathological prognostic factors in breast
cancer. The value of histologic grade in breast cancer: expe-
rience ... purposes)
PAR1 expression in breastcancer patientsFigure 1
PAR1 expression in breastcancer patients. Western blots showing PAR and EGFR expression profiles of tumor biopsy
samples from patients with infiltrating ... prognostic factor
for invasive breast cancer. Indeed, we found that the clin-
ical status or stage of breastcancer in our patients was cor-
related with PAR1 overexpression: patients overexpressing
PAR1...
... examined in breastcancerpatients after treat-
ment. Therefore, we use data from a randomized clinical
trial investigating several follow-up strategies for cura-
tively treated breastcancerpatients ... good prognosis, breastcancer is the
most prevalent cancer in the world today [1]. After cura-
tive treatment forbreast cancer, women attend frequent
follow-up visits to be examined for possible ... group program after
curative treatment forbreastcancer (MaCare trial, ISRCTN
74071417) [10]. Patients in the trial were all female,
treated forbreastcancer with curative intent, and had no
concomitant...
... nanocapsule form. This observation
was consistent with a previous report [48] related to a nanoparticulate form of another
anticancer drug (doxorubicin) tested on a different breastcancer cell ... characterized for particle size,
zeta potential, EE%, drug release kinetics, morphology, crystallinity, and cytotoxicity on the
SUM 225 breastcancer cell line by dynamic light scattering, high performance ... acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Encapsulation of docetaxel in oily core polyester nanocapsule intended for
breastcancer therapy
Nanoscale...
... the for-
mer, the most used in Europe forbreastcancer are the
European Organization for Research and Treatment of
Cancer Core Cancer Quality Life Questionnaire
(EORTC QLQ-C30) and its breast- cancer- speci ... health-related quality of life
for women with breast cancer. BreastCancer Res Treat 2005, 93:217-226.
57. Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA:
Breast cancer in older women: ... European
Organization for Research and Treatment of Cancer; EORTC QLQ-BR23:
European Organization for Research and Treatment of Cancer Quality Life
Questionnaire BreastCancer Specific Module;...
... in
human breastcancer cells and therefore have considerable
potential for treatment of breast cancer.
Keywords Nanoparticles Á MDR Á Pluronic F68 Á
Poly (e-caprolactone) Á Docetaxel Á Breast cancer
Introduction
Cancer ... multidrug resistance in
human breastcancer cells and therefore have considerable
potential for treatment of breast cancer.
Acknowledgments The authors are grateful for financial support
from the ... 54.37% for Taxotere
Ò
to 49.16% (i.e. a
11.42% increase in cytotoxicity, p [ 0.05) for PCL NP
formulation and 36.63% (i.e. a 38.88% increase in cyto-
toxicity, p \0.05) for PCL/Pluronic F68 NP formulation.
Similarly,...
... treatment is therefore not as effective as it
should be. Mortality due to breastcancer is decreasing in
most western countries, because of mass screening, frequent
use of post-operative chemotherapy ... understood breastcancer heterogeneity
better. Two recent papers in Genome Biology from the
laboratories of Carlos Caldas [1] and Eric Miska [2] use
molecular methods to classify breast cancers ... hheetteerrooggeenneeiittyy
Because breastcancer heterogeneity arises from many
different factors, several directions of research must be
pursued simultaneously if we are to understand and cope
with the different forms of breast...
...
does it relate to breastcancer in African-American women?
Cancer, 2005, 103(8): 1540-1550.
15. Collaborative Group on Hormonal Factors in Breast Cancer.
Breast cancer and breastfeeding: collaborative ... refined foods and chemical
food additives, and decreased intake of fresh fruits and
vegetables.
Single cases are not generally accepted for genetic
testing for hereditary breastcancer genes ...
BRCA1 mutations to breastcancer in a North African population, we analysed genomic DNA from breastcancer
cases ascertained in Algiers.
Both familial cases (at least three breast cancers in the...
... C-reactive protein level
in breastcancer patients
Praveen Ravishankaran
1*
, R Karunanithi
2
Abstract
Background: Breastcancer is a disease that continues to plague females during their entire lifetime. ... IL-6 and CRP in breast carcinoma, and to correlate them with the staging of the disease and the prognosis.
Methods: 59 female patients admitted forbreastcancer were identified for the study and ... JL: Confirmation of a prognostic index in primary breast cancer.
Br J Cancer 1987, 56:489-492.
14. Lonn U, Lonn S, Nilsson B, Stenkvist B:
Breast cancer: prognostic
significance
of c-erb-B2 and...
... CS, Nelson BK: Seroma formation
following breastcancer surgery. Breast J 2003, 5:385-8.
10. Woodworth PA, McBoyle MF, Helmer SD, Beamer RL: Seroma formation
after breastcancer surgery: incidence ... of
seromas following breastcancer surgeries: seromas following breast
cancer surgeries. Breast J 2007, 13:588-92.
21. Burak WE Jr, Goodman PS, Young DC, Farrar WB: Seroma formation
following ... Adjuvant Breast and Bowel Project: Technical
outcomes of sentinel-lymph-node resection and conventional axillary-
lymph-node dissection in patients with clinical node-negative patients
with breast cancer: ...